# US 5,706,829 A · Method for treating neurocardiogenic syncope > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,706,829 A - Document ID: US5706829A - Status: Granted - Kind: A - Application number: 08/660,798 - Filed: 1996-06-06 - Granted: 1998-01-13 - Earliest claimed: 1996-06-06 - Assignees: Creighton University - Inventors: Nazih Najih Kadri - Web page: https://patentgrep.com/patent/US5706829A ## CPC - A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to methods for treating neurocardiogenic syncope. The method involves administering to a patient an effective amount of a compound having the formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.5 are each selected from the group consisting of hydrogen and lower alkyl; and R.sub.3 and R.sub.4 are each selected from the group consisting of hydrogen, halogen, lower alkyl, nitro, amino, trifluoromethyl, and lower acylamino; at least one of R.sub.3 and R.sub.4 being a nitrogen containing group, or a pharmaceutically acceptable salt thereof. ## Claims ### Claim 1 A method for treating neurocardiogenic syncope in a patient, said method comprising: administering to an adult from about 0.5 milligrams to about 1.5 kilograms per day, or to a child from about 0.01 milligrams per kilogram to about 0.05 milligrams per kilogram of the child's body weight per day, of a compound having the formula: ##STR10## wherein R.sub.1, R.sub.2 and R.sub.5 are each selected from the group consisting of hydrogen and lower alkyl; and R.sub.3 and R.sub.4 are each selected from the group consisting of hydrogen, halogen, lower alkyl, nitro, amino, trifluoromethyl, and lower acylamino; at least one of R.sub.3 and R.sub.4 being a nitrogen containing group, or a pharmaceutically acceptable salt thereof. ### Claim 2 (depends on 1) The method of claim 1 wherein R.sub.1, R.sub.2 and R.sub.5 are each hydrogen, R.sub.4 is nitro, and R.sub.3 is a halogen. ### Claim 3 (depends on 2) The method of claim 2 wherein R.sub.3 is chlorine. ### Claim 4 (depends on 3) The method of claim 3 wherein the compound is clonazepam. ### Claim 5 (depends on 1) The method of claim 1 wherein R.sub.1, R.sub.2 and R.sub.5 are each hydrogen, R.sub.4 is selected from the group consisting of halogen, nitro, and trifluoromethyl, and R.sub.3 is halogen. ### Claim 6 (depends on 5) The method of claim 5 wherein R.sub.3 is selected from the group consisting of fluorine and chlorine. ### Claim 7 (depends on 1) The method of claim 1 wherein the compound is contained in a slow-release microcapsule or suspension formulation. ### Claim 8 (depends on 1) The method of claim 1 wherein the compound is administered orally. ### Claim 9 (depends on 8) The method of claim 8 wherein the compound is in a tablet, capsule, granule, dispersible powder, suspension, syrup, or elixir form. ### Claim 10 (depends on 9) The method of claim 9 wherein the compound is in a tablet or capsule form and is admixed with inert diluent, granulating agent, disintegrating agent, a lubricating agent, or combinations thereof. ### Claim 11 (depends on 9) The method of claim 9 wherein the compound is in a suspension and is admixed with inert diluent, excipients, wetting agents, preservatives, or combinations thereof. ### Claim 12 (depends on 1) The method of claim 1 wherein the patient is an adult and the compound is administered in an amount from about 0.5 mg to about 1.0 mg per day. ### Claim 13 (depends on 1) The method of claim 1 wherein the patient is a child, and the compound is administered in an amount from about 0.01 mg/kg to about 0.03 mg/kg of the patient's body weight per day. ### Claim 14 A method for treating neurocardiogenic syncope in an adult patient, said method comprising: administering to the adult patient from about 0.5 mg to about 1.5 mg per day of a compound having the formula: ##STR11## wherein R.sub.3 is halogen and R.sub.4 is selected from the group consisting of halogen, nitro, and trifluoromethyl or a pharmaceutically acceptable salt thereof. ### Claim 15 (depends on 16) The method of claim 16 wherein R.sub.3 is chlorine and R.sub.4 is nitro. ### Claim 16 (depends on 17) The method of claim 17 wherein the compound is clonazepam. ### Claim 17 (depends on 16) The method of claim 16 wherein the compound is administered in an amount from about 0.5 mg to about 1.0 mg per day. ### Claim 18 A method for treating neurocardiogenic syncope in a patient wherein the patient is a child, said method comprising: administering to the patient from about 0.01 mg/kg to about 0.05 mg/kg of the patient's body weight per day of a compound having the formula: ##STR12## wherein R.sub.3 is halogen and R.sub.4 is selected from the group consisting of halogen, nitro, and trifluoromethyl or a pharmaceutically acceptable salt thereof. ### Claim 19 (depends on 18) The method of claim 18 wherein R.sub.3 is chlorine and R.sub.4 is nitro. ### Claim 20 (depends on 19) The method of claim 19 wherein the compound is clonazepam. ### Claim 21 (depends on 18) The method of claim 18 wherein the compound is administered in an amount from about 0.01 mg/kg to about 0.03 mg/kg of the patient's body weight per day.